• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [23156 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2009     Committee for New Health Technology Assessment (CNHTA) [Epstein-Barr virus VCA IgA]
2009     Committee for New Health Technology Assessment (CNHTA) [Epstein-Barr virus EA IgA]
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Eposterior tibial nerve stimulation in overactive bladder and bowel incontinence]
2004     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Epoetin (EPO) for anaemic cancer patients]
2007     The Netherlands Organisation for Health Research and Development (ZonMw) [Epileptic source localization with EEG-correlated functional MRI]
2018     Andalusian Health Technology Assessment Area (AETSA) [Epigenetic profile for the identification of primary cancer of unknown origin]
2018     Canary Health Service [Epidermal growth factor for the treatment of diabetic foot ulcers]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Epidermal growth factor (Heberprot-P®) in chronic ulcers]
2021     Austrian Institute for Health Technology Assessment (AIHTA) [Epidemiology of long COVID: a preliminary report. German short version of the original KCE report]
2003     Unit of Health Economics and Technology Assessment in Health Care (HunHTA) [Epidemiology and costs of osteoarthritis and rheumatoid arthritis in Hungary]
2008     Basque Office for Health Technology Assessment (OSTEBA) [Epidemiological analysis of information collected by hospital cancer registries in the Basque Autonomous Community. Identification of possible improvements with regard to the feedback and dissemination of results]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Epcoritamab (relapsed or refractory diffuse large B-cell lymphoma) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2011     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Enzyme replacement therapy in mucopolysaccharidoses I, II and VI; 2011]
2018     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Enzyme replacement therapy in lysosomal storage diseases: systematic review and budgetary impact. Update]
2011     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Enzymatic replacement treatment for type I gaucher's disease patients]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Enzalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Enzalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Enzalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Enzalutamide (prostate cancer) - Addendum to Commission A21-77]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Enzalutamide (prostate cancer) - Addendum to Commission A18-80]
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Enzalutamide (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2013     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Enzalutamide - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Entrectinib (solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion) - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Entrectinib (solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion) - Addendum to Commission A20-74]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Entrectinib (NSCLC) - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Entrectinib (NSCLC) - Addendum to Commission A20-75]
2011     Committee for New Health Technology Assessment (CNHTA) [Enterovirus real-time rt-pcr]
2013     Basque Office for Health Technology Assessment (OSTEBA) [Enhancing the quality of information on colorectal and prostate cancer in the population cancer register of the Basque Country (RCE) and bibliographical review]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Enfortumab vedotin (urothelial carcinoma) - Addendum to Commission A22-61]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Enfortumab vedotin (urothelial cancer) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Enfortumab vedotin (urothelial cancer) - 2nd addendum to commission A22-61]
2023     Austrian Institute for Health Technology Assessment (AIHTA) [Endovenous laser therapy for varicose veins in the lower extremities]
2022     HTA South [Endovascular valve repair in severe mitral insufficiency]
2020     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Endovascular treatment of varicose veins by radiofrequency ablation or cyanoacrylate closure]
2009     Andalusian Health Technology Assessment Area (AETSA) [Endovascular treatment of cerebrovascular disease]
2009     Andalusian Health Technology Assessment Area (AETSA) [Endovascular treatment of cerebrovascular disease]
2009     Andalusian Health Technology Assessment Area (AETSA) [Endovascular treatment of cerebrovascular disease]
2009     Andalusian Health Technology Assessment Area (AETSA) [Endovascular treatment for thoracic aorta lesions]
2009     Andalusian Health Technology Assessment Area (AETSA) [Endovascular treatment for thoracic aorta lesions]
2016     Haute Autorite de sante (HAS) [Endovascular thrombectomy of intracranial arteries]
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Endovascular thrombectomy in acute ischemic stroke]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Endovascular thrombectomy in acute ischemic stroke]
2016     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Endovascular therapy using mechanical thrombectomy devices for acute ischaemic stroke. National Report: German Summary of the correspondent EUnetHTA Report]
2015     Institute for Clinical Effectiveness and Health Policy (IECS) [Endovascular repair of thoracic and thoraco-abdominal aortic aneurysm]
2013     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Endovascular repair of aortic aneurysms]
2015     Institute for Clinical Effectiveness and Health Policy (IECS) [Endovascular repair in abdominal aortic aneurysm]
2012     Institute for Clinical Effectiveness and Health Policy (IECS) [Endovascular laser treatment versus saphenectomy for the management of varicose veins in lower limbs]
2015     Institute for Clinical Effectiveness and Health Policy (IECS) [Endovascular laser treatment of varicose veins of the lower limbs]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Endovascular implantation of a stent graft with a valve component for tricuspid regurgitation - Assessment according to §137h Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Endovascular implantation of a stent graft with a valve component for tricuspid regurgitation - Addendum to commission H20-08]
2012     The Regional Health Technology Assessment Centre (HTA-centrum) [Endovascular contra open surgical treatment of symptom generating atherosclerotic lesions of the external iliac artery]
2012     Institute for Clinical Effectiveness and Health Policy (IECS) [Endothelial cell count in subjects who underwent laser photorefractive surgery for myopia or keratoplasty for keratoconus]
2010     The Netherlands Organisation for Health Research and Development (ZonMw) [Endoscopic tri-modal imaging for improved detection of early neoplasia in the gastrointestinal tract]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Endoscopic thermoablation of the duodenal mucosa in type 2 diabetes - Addendum to commission H20-04]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Endoscopic thermal ablation of the duodenal mucosa in type 2 diabetes - Assessment according to §137h Social Code Book V]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Endoscopic surgery in patients with middle ear conditions]
2020     Institute for Clinical Effectiveness and Health Policy (IECS) [Endoscopic spine surgery for disc disease and lumbar spinal stenosis]
2011     Institute for Clinical Effectiveness and Health Policy (IECS) [Endoscopic mucosectomy for the treatment of sessile polyps ]
2017     Basque Office for Health Technology Assessment (OSTEBA) [Endoscopic mucosal resection (EMR) and endoscopic mucosal dissection (EMD) in superficial gastrointestinal tumors]
2020     Institute for Clinical Effectiveness and Health Policy (IECS) [Endoscopic full-thickness resection of colorectal lesions]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Endoscopic anti-reflux mucosectomy, ARMS]
2002     Basque Office for Health Technology Assessment (OSTEBA) [Endoscopic and radiological techniques in the diagnosis and screening of colon cancer. Evaluation of the variability of use and acceptabilityy]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Endorectal cooling accompanying prostate cancer surgery]
2018     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Endometriosis – Diagnosis, treatment and patient experiences]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Endometrial receptivity array in assisted reproduction]
2020     Institute for Clinical Effectiveness and Health Policy (IECS) [Endometrial microbiome test in assisted reproduction]
2012     Institute for Clinical Effectiveness and Health Policy (IECS) [Endometrial cell co-culture in patients receiving assisted reproduction treatments]
2010     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Endoluminal brachytherapy in the treatment of cancer of the oesophagus]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Endograft fixation]
2009     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Endobronchial valves in the treatment of diffuse heterogeneous-type pulmonary emphysema]
2014     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Endobronchial valves in emphysema]
2010     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Endobronchial valve implantation for emphysema - 2nd Update 2010]
2009     Committee for New Health Technology Assessment (CNHTA) [Endobronchial ultrasound/fine needle aspiration]
2014     Haute Autorite de sante (HAS) [Endobronchial ultrasound-guided transbronchial needle aspiration]
2012     Institute for Clinical Effectiveness and Health Policy (IECS) [Endobronchial ultrasound-guided transbronchial needle aspiration in the diagnosis of pathologies accessible by transbronchial needle aspiration requiring anatomopathological diagnosis]
2014     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [EndoBarrier® evaluation device for the treatment of morbid obesity with or without diabetes mellitus type II]
2010     Andalusian Health Technology Assessment Area (AETSA) [Endo-PAT 2000 in the diagnosis of coronary atherosclerosis]
2014     Norwegian Knowledge Centre for the Health Services (NOKC) [End-of-life care - how to find the appropriate level and intensity of medical treatment of seriously ill and dying patients]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Encorafenib (melanoma) - Benefit assessment according to §35a Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Encorafenib (melanoma) - Addendum to Commission A18-61]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Encorafenib (colorectal cancer) - Benefit assessment according to §35a Social Code Book V]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Emtricitabine/tenofovir alafenamide (HIV) - Addendum to Commission A16-30]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Emtricitabine/tenofovir alafenamide - Benefit assessment according to §35a Social Code Book V]
2012     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Emtricitabine/rilpivirine/tenofovir disoproxil - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2012     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Emtricitabine/rilpivirine/tenofovir disoproxil - Addendum to the benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Emtricitabine/rilpivirine/tenofovir alafenamide (HIV infection) - Benefit assessment according to §35a SGB V]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Empagliflozin/metformin: benefit assessment according to §35a Social Code Book V]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Empagliflozin/metformin - Addendum to Commission A16-13]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Empagliflozin/linagliptin (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Empagliflozin: benefit assessment according to §35a Social Code Book V]
2020     National Committee for Technology Incorporation (CONITEC) [Empagliflozin and dapagliflozin for the treatment of type 2 diabetes mellitus]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Empagliflozin (type 2 diabetes mellitus in children and adolescents) – Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Empagliflozin (renal insufficiency) - Benefit assessment according to § 35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Empagliflozin (heart failure) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Empagliflozin (heart failure) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Empagliflozin (heart failure) - Addendum to Commission A21-93]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Empagliflozin (heart failure and preserved ejection fraction) - Addendum to Commission A22-39]
2014     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Empagliflozin - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Empagliflozin - Addendum to Commission A16-12]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Emotional freedom technique]